SAN DIEGO, HONG KONG and BEIJING, April 17 /PRNewswire-FirstCall/ -- Bridgetech Holdings International, Inc., a company focused on maximizing the potential of emerging healthcare products and services in the US and Asian markets, announced today that it has agreed to be the anchor sponsor for the 2007 Asia-Pacific Conference of Tumor Biology and Medicine, a major international event hosted annually by the Chinese Anti-Cancer Association (CACA). This year’s conference will be held at Beijing’s 301 Hospital from 15-17 September 2007.
Themed ‘Caring for Life and Health: Scientific Therapeutics and Prevention of Cancer’, the conference is also the first Oncology Summit of the 301 Hospital and the second Chinese Middle-age and Youth Oncologist Forum. Bridgetech has confirmed speakers from top US institutions including MD Anderson Cancer Center, Mary Crowley Medical Research Clinic, National Cancer Institute and University of California, Los Angeles. More than 1,000 participants and over 50 speakers from both China and the US are expected to attend this major oncology conference in China later this year.
“Bridgetech is exceedingly pleased and privileged to be able to contribute to this significant medical education event. This is consistent with our mission to expand international oncology collaboration,” said Michael Chermak, Chairman and CEO of Bridgetech. “Further, this supports our business model of introducing cutting edge oncology products to China.”
CACA annually holds an academic and science conference on cancer with a view to promoting international communication, to publish academic periodicals, and to popularize prevention knowledge of cancer. Deputy Secretary General of CACA Professor Li Chunhai stated, “We are most pleased to have Bridgetech’s involvement in this conference. Their support not only enriches the conference offerings, but also provides a valuable opportunity for direct international exchange on the important topic of oncology and healthcare. The 301 Hospital is responsible for the medical treatment of China’s state leaders and has access to the most advanced medical technologies. We are very grateful for their agreement to host this year’s conference at their hospital.”
Besides 301 Hospital and CACA, other organizers include the Tumor Marker Committee and the Clinical Application Biochemistry and Molecule Biochemistry Branch of the Chinese Biochemistry and Molecule Biology Society. The co-organizer of the conference is the Sino-US Medical Exchange Foundation.
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and the US to capitalize on the demand for Western healthcare in Greater China. The company is bringing emerging drugs, devices and diagnostics to Greater China, with an initial focus on oncology. For additional information, please visit Bridgetech at www.bthi.com
About Chinese Anti-Cancer Association (CACA)
CACA was established in 1984 and is now oversighted by the China Association of Science and Technology. Registered under the Ministry of Civil Affairs, CACA is a non-profit association of the first category in China and has a network of member anti-cancer organizations throughout the country at provincial and local levels. CACA has over 30,000 members.
CACA aims its utmost efforts at organizing scientific cooperation and conferences. It promotes international non-governmental exchanges, conducts various training courses and seminars and nurtures scientific, technological and medical professionals in the field of oncology, besides compiling and publishing academic periodicals and mobilizing other forces in the community to take part in the promotion and dissemination of the tumor prevention knowledge. For additional information, please visit www.caca.org.cn.
About 301 Hospital
The 301 Hospital is China’s largest military hospital. This 4,700-bed hospital is a leader in providing clinical and medical technology. The hospital treats more than 80,000 in-patients, manages over 2.5 million outpatient visits and 40,000 surgeries per year. It is also the center for the armed forces faculty, medical research institute and other key laboratories. For additional information, please visit www.301hospital.com.cn.
Forward-Looking Statements.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning expectations, beliefs, goals, intention or strategies for the future of Bridgetech. Forward-looking statements may be identified by words such as “goals,” “plans,” “believes,” “will,” “expects” and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. Investors are cautioned not to place any undue reliance on any forward-looking statements.
Contacts: Media Relations: Vince Heald, Beck Ellman Heald - 858-453-9600 vheald@behmedia.com Investor Relations: Redwood Consultants, LLC - 415-884-0348
Bridgetech Holdings International, Inc.
CONTACT: Media Relations, Vince Heald of Beck Ellman Heald,+1-858-453-9600, vheald@behmedia.com; or Investor Relations, RedwoodConsultants, LLC, +1-415-884-0348, both for Bridgetech HoldingsInternational, Inc.
Web site: http://www.bthi.com/
